A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel AssignmentStudy to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects withRelapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell AcuteLymphoblastic Leukemia (B-ALL)
Sponsor: |
Precision BioSciences, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS9400 |
U.S. Govt. ID: |
NCT03666000 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR0191 to treat certain types of cancers. PBCAR0191 is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR0191 came from people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
Investigator
Ran Reshef, MD
Are you 18 years of age or older? |
Yes |
No |
Have you been diagnosed with leukemia or lymphoma? |
Yes |
No |
Have you received at least 2 prior chemotherapy treatment regimens? |
Yes |
No |